Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

How to detour Treg cells in T cell-based antitumor immune therapy.

Zheng S, Shen Y, Song Y, Yuan Y.

Onco Targets Ther. 2013 Sep 6;6:1243-7. doi: 10.2147/OTT.S48872. eCollection 2013.

2.

Targeting regulatory T cells in tumors.

Liu C, Workman CJ, Vignali DA.

FEBS J. 2016 Jul;283(14):2731-48. doi: 10.1111/febs.13656. Epub 2016 Mar 1. Review.

PMID:
26787424
3.

Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Haase D, Starke M, Puan KJ, Lai TS, Rotzschke O.

Immunol Res. 2012 Sep;53(1-3):200-12. doi: 10.1007/s12026-012-8267-9. Review.

PMID:
22418725
4.
5.

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G.

PLoS One. 2013 Jun 14;8(6):e65757. doi: 10.1371/journal.pone.0065757. Print 2013.

6.

Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.

Coutinho A, Caramalho I, Seixas E, Demengeot J.

Curr Top Microbiol Immunol. 2005;293:43-71. Review.

PMID:
15981475
7.

Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.

Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA.

J Immunol. 2009 Sep 15;183(6):3682-9. doi: 10.4049/jimmunol.0900560. Epub 2009 Aug 19.

8.

Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.

Shen X, Li N, Li H, Zhang T, Wang F, Li Q.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1745-54. doi: 10.1007/s00432-010-0833-8. Epub 2010 Mar 10.

PMID:
20221638
9.

Regulatory T cells in cancer immunotherapy.

Nishikawa H, Sakaguchi S.

Curr Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14. Review.

PMID:
24413387
10.

[The Role of Regulatory T-cells in Antitumor Immune Response].

Klabusay M.

Klin Onkol. 2015;28 Suppl 4:4S23-7. Review. Czech.

PMID:
26647885
11.
13.

Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.

Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F, Yoshizawa H.

J Immunol. 2005 Oct 15;175(8):5058-66.

14.

Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D.

Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13.

PMID:
24780112
15.

T-cell regulatory mechanisms in specific immunotherapy.

Jutel M, Akdis CA.

Chem Immunol Allergy. 2008;94:158-77. doi: 10.1159/000155000. Review.

PMID:
18802346
16.

CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.

Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, Urba WJ, Hu HM.

Eur J Immunol. 2010 May;40(5):1375-85. doi: 10.1002/eji.200839210.

17.

Cellular immune responses towards regulatory cells.

Larsen SK.

Dan Med J. 2016 Jan;63(1):B5188. Review.

PMID:
26726907
18.

In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes.

Sacchetti C, Rapini N, Magrini A, Cirelli E, Bellucci S, Mattei M, Rosato N, Bottini N, Bottini M.

Bioconjug Chem. 2013 Jun 19;24(6):852-8. doi: 10.1021/bc400070q. Epub 2013 May 22.

PMID:
23682992
19.

Tumor regulatory T cells potently abrogate antitumor immunity.

Liu Z, Kim JH, Falo LD Jr, You Z.

J Immunol. 2009 May 15;182(10):6160-7. doi: 10.4049/jimmunol.0802664.

20.

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF.

Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696.

Supplemental Content

Support Center